68Ga-NOTA功能化泛素抗菌肽:细胞毒性、生物分布、辐射剂量学及感染首次人体PET/CT显像
本研究评估68Ga-NOTA-UBI的细胞毒性、生物分布与辐射剂量学,并在非人灵长类、2名健康志愿者和3例疑似感染患者中进行PET/CT显像。结果显示NOTA-UBI细胞毒性可忽略,人体膀胱壁为剂量关键器官(185 μSv/MBq),68Ga-NOTA-UBI可诊断3例患者的骨与软组织感染。
要点
- 68Ga-NOTA-UBI在Vero细胞和MT-4白细胞中细胞毒性可忽略。
- 人体辐射剂量估算显示膀胱壁为剂量关键器官(185 μSv/MBq),肾脏次之(23 μSv/MBq),有效剂量估计为17 μSv/MBq。
- 68Ga-NOTA-UBI可诊断3例患者的骨与软组织感染。
核心结论
- 68Ga-NOTA-UBI被认为是一种无毒、可安全给药且不太可能引起人体不良反应的放射性药物。
- 良好的示踪剂生物分布和首次人体结果将使68Ga-NOTA-UBI PET/CT成为具有辅助临床相关性的、令人鼓舞的未来诊断技术。
研究设计与样本
- 在绿猴肾上皮(Vero)细胞和MT-4白细胞中评估细胞毒性,并在体外用不同细菌和真菌菌株研究示踪剂敏感性。
- 在非人灵长类动物中进行基于PET/CT的生物分布、药代动力学和辐射剂量学评估。
- 2名健康志愿者和3例疑似感染患者接受68Ga-NOTA-UBI PET/CT显像。
主要发现
- NOTA-UBI的细胞毒性可忽略。
- 68Ga-NOTA-UBI在非人灵长类动物中显示中等血液清除(半衰期29分钟)和主要经肾脏清除。
- 人体辐射剂量估算显示膀胱壁为剂量关键组织(185 μSv/MBq),其次为肾脏(23 μSv/MBq);全身总吸收剂量低(<7 μSv/MBq);有效剂量估计为17 μSv/MBq。
- 68Ga-NOTA-UBI可诊断3例患者中的3例骨与软组织感染。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ubiquicidin is an antimicrobial peptide with great potential for nuclear imaging of infectious diseases, as its cationic-rich fragment TGRAKRRMQYNRR (UBI) has been functionalized with NOTA to allow complexation to 68Ga (68Ga-NOTA-UBI). We herein assess the cytotoxicity and radiation dosimetry for 68Ga-NOTA-UBI and a first-in-human evaluation to diagnose infectious processes. Methods: Cytotoxicity was evaluated in green monkey kidney epithelial (Vero) cells and MT-4 leukocytes. Tracer susceptibility was studied in vitro using different bacterial and fungal strains. PET/CT-based biodistribution, pharmacokinetics, and radiation dosimetry were performed on nonhuman primates. Two healthy volunteers and 3 patients with suspected infection underwent 68Ga-NOTA-UBI PET/CT imaging. Results: Negligible cytotoxicity was determined for NOTA-UBI. 68Ga-NOTA-UBI showed moderate blood clearance (29-min half-life) and predominant renal clearance in nonhuman primates. Human radiation dose estimates indicated the bladder wall as the dose-critical tissue (185 μSv/MBq), followed by the kidneys (23 μSv/MBq). The total absorbed body dose was low (<7 μSv/MBq); the effective dose was estimated at 17 μSv/MBq. 68Ga-NOTA-UBI could diagnose bone- and soft-tissue infection in 3 of 3 patients. Conclusion:68Ga-NOTA-UBI is considered a nontoxic, safe-to-administer radiopharmaceutical unlikely to cause adverse effects in humans. The favorable tracer biodistribution and the first-in-human results will make 68Ga-NOTA-UBI PET/CT an encouraging future diagnostic technique with auxiliary clinical relevance.
引用
- Ebenhan T, Sathekge MM, Lengana T, et al. 68Ga-NOTA-Functionalized Ubiquicidin: Cytotoxicity, Biodistribution, Radiation Dosimetry, and First-in-Human PET/CT Imaging of Infections. J Nucl Med. 2017. PMID: 29051342. doi:10.2967/jnumed.117.200048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。